Research and drug development activities in rare diseases: differences between Japan and Europe regarding influence of prevalence
| Autor: | Shingo Kano, Hirokuni Mizoguchi, Takayuki Yamanaka |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Pharmacology Publishing Biomedical Research business.industry Biotechnology Orphan drug Europe 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Rare Diseases Drug development Japan 030220 oncology & carcinogenesis Environmental health Drug Discovery Prevalence Medicine Cluster Analysis Humans business Regional differences Rare disease |
| Zdroj: | Drug discovery today. 21(10) |
| ISSN: | 1878-5832 |
| Popis: | Orphan drug legislation has contributed enormously to promote drug development for rare diseases but further effective and sustainable approaches are required. This study focused on the difference of rare disease prevalence between Japan and Europe, classified the rare diseases comprehensively using cluster analysis and analyzed the influence of prevalence on research activity and drug development. Although overall strong correlative progress of research was found and absolute numbers of values were greater in Europe than in Japan, the regional higher prevalent diseases demonstrated more progress of research and development relatively in the region by examining clusters. Our findings suggest potential optimal drug development in consideration of regional differences. Moreover, an in-depth analysis of diseases that showed exceptional research achievements compared with prevalence speculated important determinants of progress. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect